No Data
UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $60 price target.
UroGen Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 257.57% HC Wainwright & Co. $60 → $60 Reiterates Buy → Buy 06/14/2024 218.83% Ladenburg Thalman
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright analyst Ram Selvaraju maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 36.9
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $102
TD Cowen analyst Tara Bancroft maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and sets the target price at $102.According to TipRanks data, the analyst has a success rate of 50.0% and a tot
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Maintains Target Price $22
Goldman Sachs analyst Paul Choi maintains $UroGen Pharma Ltd(URGN.US)$ with a hold rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 0.0% and